Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG984

—

9b0f4477-553e-5d14-8df1-76153036b6c8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MITOTIC_SPINDLE+0.485
  • HEDGEHOG_SIGNALING+0.465
  • G2M_CHECKPOINT+0.414
  • ANGIOGENESIS+0.342
  • NOTCH_SIGNALING+0.283
  • PROTEIN_SECRETION+0.280
  • WNT_BETA_CATENIN_SIGNALING+0.266
  • HYPOXIA+0.235
  • E2F_TARGETS+0.230
  • HEME_METABOLISM+0.219

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.450
  • INTERFERON_ALPHA_RESPONSE-0.278
  • ALLOGRAFT_REJECTION-0.212
  • INTERFERON_GAMMA_RESPONSE-0.208
  • DNA_REPAIR-0.129
  • MYC_TARGETS_V1-0.129
  • IL6_JAK_STAT3_SIGNALING-0.113
  • FATTY_ACID_METABOLISM-0.103
  • PI3K_AKT_MTOR_SIGNALING-0.081
  • XENOBIOTIC_METABOLISM-0.076

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG670
mng-umap@100
——0.779
2MNG471
mng-umap@100
——0.761
3TCGA-CR-7365-01A-11R-2016-07
head-neck@1
——0.743
4SRR17866829
colon-landscapes@1
——0.729
520040086.TNBC
breast-umap@18
—C0.708
6TCGA-56-7582-01A-11R-2045-07
lung-landscapes@6
—cohortSQ20.707
7TCGA-85-A50M-01A-21R-A262-07
lung-landscapes@6
—cohortSQ10.706
8MDT-AP-0007
medullo-epn-umap@date-based
MedMedulloblastoma0.703
9MNG1272
mng-umap@100
——0.697
10TCGA-F7-8298-01A-11R-2403-07
head-neck@1
——0.697

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MITOTIC_SPINDLE0.485Inavolisib— uncovered
HEDGEHOG_SIGNALING0.465Inavolisib— uncovered
G2M_CHECKPOINT0.414Inavolisib— uncovered
ANGIOGENESIS0.342Remibrutinib— uncovered
NOTCH_SIGNALING0.283Inavolisib— uncovered
PROTEIN_SECRETION0.280Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.266Inavolisib— uncovered
HYPOXIA0.235Idelalisib— uncovered
E2F_TARGETS0.230Inavolisib— uncovered
HEME_METABOLISM0.219Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.194Inavolisib— uncovered
MYOGENESIS0.194Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.190Inavolisib— uncovered
APICAL_JUNCTION0.181Inavolisib— uncovered
GLYCOLYSIS0.155Inavolisib— uncovered
APICAL_SURFACE0.137Temsirolimus— uncovered
BILE_ACID_METABOLISM0.130Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.126Remibrutinib— uncovered
ANDROGEN_RESPONSE0.108Inavolisib— uncovered
KRAS_SIGNALING_DN0.104Remibrutinib— uncovered